AlphaQuest LLC Acquires 26,748 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

AlphaQuest LLC boosted its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 6,911.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,135 shares of the company’s stock after buying an additional 26,748 shares during the quarter. AlphaQuest LLC owned approximately 0.06% of Y-mAbs Therapeutics worth $212,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $44,000. Intech Investment Management LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $133,000. Empire Financial Management Company LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter valued at approximately $210,000. SG Americas Securities LLC raised its holdings in Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after purchasing an additional 4,163 shares during the last quarter. Finally, Principal Financial Group Inc. bought a new position in Y-mAbs Therapeutics during the 3rd quarter worth approximately $267,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 1.3 %

NASDAQ YMAB opened at $4.67 on Monday. The company has a fifty day simple moving average of $5.97 and a 200 day simple moving average of $10.10. Y-mAbs Therapeutics, Inc. has a 12-month low of $4.25 and a 12-month high of $17.78. The company has a market cap of $211.17 million, a P/E ratio of -8.65 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million during the quarter, compared to analyst estimates of $26.70 million. During the same period in the previous year, the business posted ($0.02) EPS. Sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 22.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

YMAB has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Morgan Stanley lowered their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Oppenheimer initiated coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. Bank of America lowered their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Finally, Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a report on Thursday, December 5th. They set a “buy” rating and a $17.00 price target for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Y-mAbs Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.30.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.